BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Proteologics, Ltd., GlaxoSmithKline (GSK) Extend Research Collaboration


3/19/2013 7:01:58 AM

REHOVOT, Israel, March 18, 2013 /PRNewswire/ -- Proteologics Ltd. (PRTL.TA), a leading drug developer based on the ubiquitin system, announced today that, under the terms of the 3- year original collaboration agreement signed with GSK in March 2010, the parties have agreed to extend the collaboration for an additional year.

Josh Levine, the CEO of Proteologics commented: "We are appreciative of the excellent working relationship and confidence that GSK has in Proteologics to allow GSK to extend the collaboration. Proteologics is hopeful that by the end of the collaboration we will be able to deliver to GSK a selective inhibitor of an E3 Ligase, the most selective intervention point in the ubiquitin system."

About Proteologics:

Proteologics is a leading drug discovery company focusing on small molecule inhibitors of the ubiquitin system. Professors Avram Hershko and Aaron Ciechanover, the 2004 Nobel Laureates for the discovery of the ubiquitin system, are actively involved with the company and lead the company's Scientific Advisory Board. Proteologics has entered into a number of collaborations including with GSK as well as leading labs around the world. Proteologics is a public company, traded on the Tel Aviv Stock Exchange and has leading investors including GSK and leading Israeli biotech companies and venture funds.

For more information, contact Avishai Levy, avishai@proteologics.com or +972-8-9475666


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->